CRO's leading company, Pharmaceuticals, announced the acquisition of a 60% stake in Mingjie Pharmaceuticals

, Pharmaceutical Mingkang announced the successful acquisition of Nanjing Mingjie Biopharmaceutical Testing Co., Ltd. ("Mingjie Pharmaceuticals") 60% of the shares. Upon completion of the acquisition, Miner Pharma will become a controlling subsidiary of Pharmaceuticals and will continue to focus on building third-party drug quality control and analysis laboratories that comply with global pharmaceutical regulations.According to public information, the acquisition of Mingjie Pharmaceuticals will help to expand its capabilities and scale in the field of drug quality analysis, enhance the company's ability to provide a diversified customer base from registration to production release of a full range of drug quality research services, and thus promote the upgrading of relevant industry standards, enabling customers of the new drug research and development process.Mr. Gu Kai, General Manager of Mingjie Pharmaceuticals, said, "MingJie's addition to Mingkangde will help to enhance MingJie Pharmaceutical's full range of platform capabilities in technology, commerce, operation and quality systems, providing customers with high-quality, high standards, high-time drug quality control and analysis services." Hu Zhengguo, vice chairman and global chief investment officer ofPharmaceuticals, said: "This acquisition will help Pharmaceuticals to further enhance the quality analysis service capabilities and scale of drugs, better help customers shorten the research and development cycle of new drugs, and achieve the great vision of 'making the world a drug that is not difficult to do, a disease that is difficult to treat'."According to Sky Eye, since 2014, Pharmaceutical Mingkang has participated in 47 public investment events, has merged and acquired AppTec, Jinshi Jiecheng, Meixino, Crelux, Huiyuan Bio and Pharmapace and other enterprises, invested in Jinxin Reproductive, Hualin Pharmaceuticals, Engine Biosciences and other domestic and foreign innovative drugs and their industrial chain-related enterprises. In February this year, the company through its wholly-owned subsidiary Pharmaceutical Ming Fund, the first phase of investment in the field of rare drugs in Beihai Kangcheng, indirectly improve the field of rare diseases in the field of new drug research and development services, accelerate the integration of the CRO industry chain.Industry analysis, CRO giants are constantly using the extension of the way to fill the shortage of areas, industry concentration also immediately increased. Behind a series of investment events is the accelerated integration of the CRO industry chain, as a market capitalization of nearly 240 billion yuan CRO leader, it built a moth more and more wide. (Biological exploration)